These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 10207539)

  • 1. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.
    Kirk O; Katzenstein TL; Gerstoft J; Mathiesen L; Nielsen H; Pedersen C; Lundgren JD
    AIDS; 1999 Jan; 13(1):F9-16. PubMed ID: 10207539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
    Cameron DW; Japour AJ; Xu Y; Hsu A; Mellors J; Farthing C; Cohen C; Poretz D; Markowitz M; Follansbee S; Angel JB; McMahon D; Ho D; Devanarayan V; Rode R; Salgo M; Kempf DJ; Granneman R; Leonard JM; Sun E
    AIDS; 1999 Feb; 13(2):213-24. PubMed ID: 10202827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
    Hall CS; Raines CP; Barnett SH; Moore RD; Gallant JE
    AIDS; 1999 Jul; 13(10):1207-12. PubMed ID: 10416524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
    Rockstroh JK; Bergmann F; Wiesel W; Rieke A; Thiesen A; Fätkenheuer G; Oette M; Carls H; Fenske S; Nadler M; Knechten H
    AIDS; 2000 Jun; 14(9):1181-5. PubMed ID: 10894282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure.
    Deeks SG; Grant RM; Beatty GW; Horton C; Detmer J; Eastman S
    AIDS; 1998 Jul; 12(10):F97-102. PubMed ID: 9677159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.
    Gisolf EH; Jurriaans S; Pelgrom J; van Wanzeele F; van der Ende ME; Brinkman K; Borst MJ; de Wolf F; Japour AJ; Danner SA
    AIDS; 2000 Mar; 14(4):405-13. PubMed ID: 10770543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
    Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
    AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
    Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
    Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
    AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.
    Young B; Fischl MA; Wilson HM; Finn TS; Jensen EH; DiNubile MJ; Zeldin RK
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):478-82. PubMed ID: 12473835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.
    Katner HP; Paar DP; Nadler JP; Jensen EH; Wilson HM; Finn TS; Petruschke RA; Zeldin RK
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):483-7. PubMed ID: 12473836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.
    Rolla VC; da Silva Vieira MA; Pereira Pinto D; Lourenço MC; de Jesus Cda S; Gonçalves Morgado M; Ferreira Filho M; Werneck-Barroso E
    Clin Drug Investig; 2006; 26(8):469-79. PubMed ID: 17163279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
    Figgitt DP; Plosker GL
    Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.
    Churchill DR; Pym AS; Galpin S; Foxall R; Stainsby C; Clarke JR; Kaye S; Bloor S; Larder BA; Wills B; Sun E; Babiker AG; Back DJ; Weber JN
    AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1181-9. PubMed ID: 10480631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients.
    Casado JL; Perez-Elías MJ; Antela A; Sabido R; Martí-Belda P; Dronda F; Blazquez J; Quereda C
    AIDS; 1998 Jul; 12(11):F131-5. PubMed ID: 9708403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
    Lichterfeld M; Nischalke HD; Bergmann F; Wiesel W; Rieke A; Theisen A; Fätkenheuer G; Oette M; Carls H; Fenske S; Nadler M; Knechten H; Wasmuth JC; Rockstroh JK
    HIV Med; 2002 Jan; 3(1):37-43. PubMed ID: 12059949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
    Dragsted UB; Gerstoft J; Pedersen C; Peters B; Duran A; Obel N; Castagna A; Cahn P; Clumeck N; Bruun JN; Benetucci J; Hill A; Cassetti I; Vernazza P; Youle M; Fox Z; Lundgren JD;
    J Infect Dis; 2003 Sep; 188(5):635-42. PubMed ID: 12934178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.